Jul 2026
EFO2 promotes triple-negative breast cancer progression and reduces CD8+ T cell-mediated killing by acetylating USF1 to enhance SLC2A1-mediated glycolysis.
A novel EFO2/USF1/SLC2A1 signaling axis that modulates glycolytic metabolism and CD8⁺T cell cytotoxicity is identified, positioning EFO2 as a promising therapeutic target for TNBC treatment.
Lin Jia, Liru Li, Junning Peng et al.
· Biochemical Pharmacology · 0 citations